Besides, LCN2 has been demonstrated as a biomarker for inflammatory bowel disease (Thorsvik et al., 2017), vascular dementia (Llorens et al., 2020), neuropsychiatric lupus (Mike et al., 2019), and subarachnoid hemorrhage outcome (Yu et al., 2021). This evidence concerns the gene LCN2 and inflammatory bowel disease.